IDEXX Laboratories, Inc. $IDXX Shares Purchased by Beacon Investment Advisory Services Inc.

Beacon Investment Advisory Services Inc. boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.9% in the fourth quarter, Holdings Channel reports. The fund owned 62,951 shares of the company’s stock after buying an additional 6,710 shares during the quarter. IDEXX Laboratories makes up about 1.7% of Beacon Investment Advisory Services Inc.’s holdings, making the stock its 15th biggest holding. Beacon Investment Advisory Services Inc.’s holdings in IDEXX Laboratories were worth $42,588,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Spire Wealth Management grew its holdings in IDEXX Laboratories by 1,096.0% during the 4th quarter. Spire Wealth Management now owns 2,117 shares of the company’s stock valued at $1,432,000 after purchasing an additional 1,940 shares in the last quarter. Eastern Bank grew its stake in shares of IDEXX Laboratories by 775.4% during the fourth quarter. Eastern Bank now owns 604 shares of the company’s stock valued at $409,000 after acquiring an additional 535 shares in the last quarter. LVW Advisors LLC grew its stake in shares of IDEXX Laboratories by 8.9% during the fourth quarter. LVW Advisors LLC now owns 439 shares of the company’s stock valued at $297,000 after acquiring an additional 36 shares in the last quarter. Global X Japan Co. Ltd. increased its position in shares of IDEXX Laboratories by 395.9% during the fourth quarter. Global X Japan Co. Ltd. now owns 3,516 shares of the company’s stock worth $2,379,000 after acquiring an additional 2,807 shares during the last quarter. Finally, Mather Group LLC. increased its position in shares of IDEXX Laboratories by 1.7% during the fourth quarter. Mather Group LLC. now owns 1,474 shares of the company’s stock worth $997,000 after acquiring an additional 25 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 2,693 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the completion of the transaction, the executive vice president directly owned 19,899 shares of the company’s stock, valued at approximately $13,163,984.46. This represents a 11.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sophie V. Vandebroek sold 1,464 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the sale, the director owned 648 shares in the company, valued at $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 45,957 shares of company stock valued at $29,862,109 over the last ninety days. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX stock opened at $558.32 on Monday. The firm has a market cap of $44.40 billion, a price-to-earnings ratio of 42.72, a PEG ratio of 3.39 and a beta of 1.66. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The firm has a fifty day moving average price of $631.32 and a two-hundred day moving average price of $662.08. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the firm posted $2.53 EPS. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on IDXX shares. Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. UBS Group cut their target price on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 3rd. Barclays reduced their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Finally, BTIG Research cut their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.